Guilford Gliadel Survival Data Could Address FDA “Non-Approvable” Letter
Executive Summary
Guilford Pharmaceuticals may submit Gliadel Wafer patient survival data to help address concerns outlined in FDA's March 19 "non-approvable" letter for a newly diagnosed malignant glioma indication
You may also be interested in...
Guilford Gliadel Wafer Initial Surgery Indication To Launch In First Quarter
Guilford anticipates an approval for Gliadel Wafer in newly diagnosed malignant glioma during the first quarter
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011